The psychedelic drug DMT may be an effective treatment for depression, according to the results of a recently published study. The research also found that the intensity of a person’s psychedelic ...

One person’s recreational drug trip might be another’s mental health boost. Research out today finds that dimethyltryptamine, better known as DMT, could be effective at treating people’s depression.

Algernon NeuroScience (AGN Neuro), a subsidiary of Algernon Pharmaceuticals Inc. AGNPF AGN AGW, has completed a feasibility study and has finalized its clinical trial design for a 40 patient phase 2 ...

A Canadian-based pharmaceutical company has received approval to conduct a clinical study of the psychedelic compound DMT as a treatment for stroke. Under the plan, pharmaceutical development company ...

VANCOUVER, British Columbia, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0 ...

Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. In ...

Benjamin holds a Master's degree in anthropology from University College London and has previously worked in the fields of psychedelic neuroscience and mental health. Benjamin holds a Master's degree ...

VANCOUVER, British Columbia, March 01, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical ...

Scientists have completed the first ever placebo-controlled investigation of the effects of the hallucinogen DMT on resting brain activity, according to a new study. Dimethyltryptamine is a ...